<DOC>
	<DOCNO>NCT02381899</DOCNO>
	<brief_summary>The purpose observational study provide additional data confirm safety profile efficacy bendamustine rituximab ( BR ) chemotherapy chronic lymphocytic leukemia patient treat routine clinical practice .</brief_summary>
	<brief_title>Observational Study CLL Patients Receiving BR</brief_title>
	<detailed_description>BR ( bendamustine , rituximab ) combination currently accept first-line treatment chronic lymphocytic leukemia ( CLL ) patient fludarabine combination chemotherapy appropriate . The objective observational study provide additional data confirm safety profile efficacy BR CLL patient treat routine clinical practice . Specific data interest : comorbid condition , CLL characteristic , adverse event , reason discontinuation BR , overall response rate , complete response rate , progression-free survival , overall survival .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Confirmed diagnosis chronic lymphocytic leukemia Patients treat BR active disease require treatment Informed consent data collection Patients treat BR within prospective clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>chronic lymphocytic leukemia</keyword>
	<keyword>bendamustine</keyword>
	<keyword>rituximab</keyword>
</DOC>